Fate Therapeutics, Inc. (FATE) News
Filter FATE News Items
FATE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FATE News Highlights
- FATE's 30 day story count now stands at 6.
- Over the past 14 days, the trend for FATE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about FATE are AXSM, CELL and HALO.
Latest FATE News From Around the Web
Below are the latest news stories about FATE THERAPEUTICS INC that investors may wish to consider to help them evaluate FATE as an investment opportunity.
Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue?Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Fate Therapeutics, Inc.'s (NASDAQ:FATE) Low P/S No Reason For ExcitementFate Therapeutics, Inc.'s ( NASDAQ:FATE ) price-to-sales (or "P/S") ratio of 3.8x might make it look like a strong buy... |
Fate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound?Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Fate Therapeutics to Present at Upcoming June Investor ConferencesSAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 a |
Cathie Wood is Selling These 12 Stocks in 2023In this article, we will take a look at Cathie Wood selling these 12 stocks in 2023. To see more such companies, go directly to Cathie Wood is Selling These 5 Stocks in 2023. After a bruising 2022, Cathie Wood’s funds slowly started to recover this year, thanks to the broader rally in the stock […] |
Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging HigherCelebrations may be in order for Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders, with the analysts delivering a... |
FATE Incurs Narrower-Than-Expected Q1 Loss on Lower ExpensesFATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023. |
Q1 2023 Fate Therapeutics Inc Earnings CallQ1 2023 Fate Therapeutics Inc Earnings Call |
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue EstimatesFate Therapeutics (FATE) delivered earnings and revenue surprises of 65.45% and 39.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |